NASDAQ:OMCL - Omnicell Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$66.83 +0.31 (+0.47 %)
(As of 01/18/2019 12:32 PM ET)
Previous Close$66.52
Today's Range$65.58 - $67.01
52-Week Range$39.75 - $79.48
Volume5,802 shs
Average Volume274,649 shs
Market Capitalization$2.63 billion
P/E Ratio371.39
Dividend YieldN/A
Beta1.2
Omnicell, Inc. provides automation and business analytics software solutions for medication and supply management in healthcare worldwide. The company operates through two segments, Automation and Analytics, and Medication Adherence. It offers Omnicell Automated Dispensing Cabinets, a dispensing system, which automates the management and dispensing of medications; SinglePointe, a software product that controls medications; AnywhereRN, a software which remotely queue medications from automated dispensing cabinets; Omnicell Analytics and Pandora Analytics reporting and data analytics tools; and Anesthesia Workstation that manages anesthesia supplies and medications. The company also provides XR2 Central Pharmacy System, a hospital pharmacy robotics system; Central and Satellite Pharmacy Manager, an automated pharmacy storage and retrieval system; Controlled Substance Management, a controlled substance inventory management system; OmniLinkRx, a prescription routing system; and WorkflowRx, an automated pharmacy storage, retrieval, and packaging system. In addition, it offers Omnicell Supply Management System, an automated dispensing system; Omnicell Tissue Center, which manages the chain of custody for bone and tissue specimens; OptiFlex MS that manages medical and surgical supplies; OptiFlex SS, a module for the perioperative areas; and OptiFlex CL, a module for the cardiac catheterization lab and other procedure areas. Further, the company provides IV Solutions; enterprise analytics and solutions; Omnicell Interface Software; Mach4 Pharma Systems Medimat, a robotic dispensing system; Omnicell SupplyX subscription software; RFID solutions; and consumable medication blister cards, packaging equipment, and ancillary products and services to institutional pharmacies. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was founded in 1992 and is headquartered in Mountain View, California.

Receive OMCL News and Ratings via Email

Sign-up to receive the latest news and ratings for OMCL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Electronic computers
Sub-IndustryHealth Care Technology
SectorMedical
Current SymbolNASDAQ:OMCL
CUSIP68213N10
Phone650-251-6100

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$716.16 million
Cash Flow$1.6026 per share
Book Value$13.64 per share

Profitability

Net Income$20.60 million

Miscellaneous

Employees2,350
Market Cap$2.63 billion
OptionableOptionable

Omnicell (NASDAQ:OMCL) Frequently Asked Questions

What is Omnicell's stock symbol?

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

How were Omnicell's earnings last quarter?

Omnicell, Inc. (NASDAQ:OMCL) announced its quarterly earnings data on Thursday, October, 25th. The company reported $0.49 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.40 by $0.09. The business had revenue of $204.27 million for the quarter, compared to analysts' expectations of $203.48 million. Omnicell had a return on equity of 7.91% and a net margin of 6.11%. View Omnicell's Earnings History.

When is Omnicell's next earnings date?

Omnicell is scheduled to release their next quarterly earnings announcement on Thursday, February 7th 2019. View Earnings Estimates for Omnicell.

What price target have analysts set for OMCL?

6 equities research analysts have issued 1-year target prices for Omnicell's stock. Their predictions range from $55.00 to $86.00. On average, they expect Omnicell's share price to reach $73.50 in the next twelve months. This suggests a possible upside of 9.9% from the stock's current price. View Analyst Price Targets for Omnicell.

What is the consensus analysts' recommendation for Omnicell?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Omnicell.

What are Wall Street analysts saying about Omnicell stock?

Here are some recent quotes from research analysts about Omnicell stock:
  • 1. According to Zacks Investment Research, "Over the past three months, Omnicell has outperformed its industry. The company continued to see solid uptake of Omnicell XT. It also entered various deals for the XR2 and IVX Workflow products. Bookings and product backlogs also rose in the quarter. We are encouraged to note that the company is working on product innovation through R&D. Also, Omnicell is expected to gain from launches, partnerships and digital transformation. However, increasing operating expenses are putting pressure on the bottom line for Omnicell. A resilient hospital capital expenditure environment might affect the adoption of the company’s solutions. Tough competitive landscape is a dampener as well." (1/16/2019)
  • 2. Cantor Fitzgerald analysts commented, ". We continue to rate OMCL shares at Overweight but increase our 12-month price target to $80 from $70. We recently attended the mid- year meeting of the Pharmacists (ASHP). ASHP is the company’s most important trade show. During the show, the company hosted a small analyst event and highlighted its newest product offerings. Specifically, it appears as though the company is making good progress with its XR2 and IVX automation products. However, the key focus appears to be on software and data analytics, in order to create work flow efficiencies for hospitals and pharmacies." (12/6/2018)

Has Omnicell been receiving favorable news coverage?

Media headlines about OMCL stock have trended somewhat positive on Friday, according to InfoTrie Sentiment Analysis. The research firm identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Omnicell earned a media sentiment score of 0.7 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future.

Who are some of Omnicell's key competitors?

Who are Omnicell's key executives?

Omnicell's management team includes the folowing people:
  • Mr. Randall A. Lipps, Founder, Exec. Chairman, Pres & CEO (Age 62)
  • Mr. Peter J. Kuipers, Exec. VP & CFO (Age 47)
  • Mr. Daniel S. Johnston, Exec. VP, Chief Legal & Admin. Officer and Corp. Sec. (Age 55)
  • Mr. Robin G. Seim, Pres of Global Automation & Medication Adherence (Age 59)
  • Mr. Joseph Brian Spears, VP of Corp. Fin. & Chief Accounting Officer (Age 59)

Who are Omnicell's major shareholders?

Omnicell's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Copper Rock Capital Partners LLC (0.93%), Summit Creek Advisors LLC (0.58%), Pwmco LLC (0.39%), Scout Investments Inc. (0.35%), Juncture Wealth Strategies LLC (0.04%) and Louisiana State Employees Retirement System (0.04%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, J Christopher Drew, James T Judson, Jorge R Taborga, Nhat H Ngo, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Sara J White. View Institutional Ownership Trends for Omnicell.

Which major investors are selling Omnicell stock?

OMCL stock was sold by a variety of institutional investors in the last quarter, including Copper Rock Capital Partners LLC, Scout Investments Inc., Pwmco LLC, Summit Creek Advisors LLC, Juncture Wealth Strategies LLC and Louisiana State Employees Retirement System. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, Gary S Petersmeyer, James T Judson, Jorge R Taborga, Nhat H Ngo, Peter J Kuipers, Randall A Lipps and Robin Gene Seim. View Insider Buying and Selling for Omnicell.

Which major investors are buying Omnicell stock?

OMCL stock was purchased by a variety of institutional investors in the last quarter, including Virtu Financial LLC, Fox Run Management L.L.C., First Hawaiian Bank, Meeder Asset Management Inc. and State of Alaska Department of Revenue. View Insider Buying and Selling for Omnicell.

How do I buy shares of Omnicell?

Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Omnicell's stock price today?

One share of OMCL stock can currently be purchased for approximately $66.85.

How big of a company is Omnicell?

Omnicell has a market capitalization of $2.63 billion and generates $716.16 million in revenue each year. The company earns $20.60 million in net income (profit) each year or $0.18 on an earnings per share basis. Omnicell employs 2,350 workers across the globe.

What is Omnicell's official website?

The official website for Omnicell is http://www.omnicell.com.

How can I contact Omnicell?

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected]


MarketBeat Community Rating for Omnicell (NASDAQ OMCL)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  359 (Vote Outperform)
Underperform Votes:  250 (Vote Underperform)
Total Votes:  609
MarketBeat's community ratings are surveys of what our community members think about Omnicell and other stocks. Vote "Outperform" if you believe OMCL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OMCL will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/18/2019 by MarketBeat.com Staff

Featured Article: Cost of Equity

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel